Journal Club: Intrathecal effects of daclizumab treatment of multiple sclerosis

The topic of this Journal Club is a study by Bielekova et al., 1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated patients. BACKGROUND AND SIGNIFICANCE Multiple